



Dr Nasser Azli joins Tollys Scientific Advisory Board

Lyon France December 15, 2021. Tollys, a biopharmaceutical company developing TL-532, the first anti-cancer immunotherapy based on a synthetic agonist specific to the Toll-like receptor 3 (TLR3), announced today that Dr. Nasser Azli will be joining its Scientific Advisory Board chaired by Professor Jean Yves Blay, who is also Director of the Leon Bérard Centre and Director of the Lyon Cancer Research Centre.

"We are delighted to welcome Dr Nasser Azli to our Scientific Advisory Board," said Vincent Charlon, CEO of Tollys. "As an expert in clinical oncology and drug development, Nasser is a highly valuable addition to our Scientific Advisory Board, particularly in view of the upcoming first clinical trials of our drug candidate TL-532".

Nasser Azli is a medical oncologist with over 30 years of academic and pharmaceutical experience. He has led the global development of several early and late-stage compounds and has contributed to the development and registration of several anti-cancer drugs, including cytotoxic, monoclonal antibodies and small molecules. He has extensive experience in experimental and translational medicine.

He obtained his medical degree from the University of Constantine and his medical degree in clinical oncology from the University of Paris VI with a fellowship and training at the Institut Gustave Roussy, Villejuif.

He joined the pharmaceutical industry in 1992, first at Rhône-Poulenc Rorer (later Aventis/Sanofi) as Director of Oncology, then at Wyeth Pharmaceuticals (later Pfizer) as Head of Oncology for Europe, at Roche (2004-2011) as Translational Medicine Leader and then at Covance as Global Head of Oncology.

From March 2014 until today, he has been an independent drug development consultant in oncology and haemato-oncology and has helped several international biotech and medical engineering companies to obtain clinical authorization applications (INDs), launch FIH studies and establish global public-private partnerships.

Dr Azli joins other prominent members of Tollys' Scientific Advisory Board:

- Prof. Jean Yves Blay
- Dr Jean Pierre Abastado
- Dr Jean Pierre Armand
- Dr Bruno Osterwalder

About TL-532

Tollys has discovered and patented a family of TLR3 agonists and has selected TL-532 as its lead candidate. TL-532 is a structurally defined, synthetically produced, double-stranded RNA that is highly specific for the TLR3 receptor. The specificity for the TLR3 receptor and its defined 70-base-pair sequence differentiates TL-532 from all other TLR3 agonists tested to date in clinical trials.

**About Tollys**

Founded in 2015, the company has raised a total of €7M from private investors to date and has secured €1.5M in funding from Bpifrance under the Deeptech program. In May 2021, Tollys was awarded the distinction of "Best-in-class therapeutic innovation" by the international board of the MATWIN program. Tollys was awarded this prize for the medical interest and industrial development potential of TL-532, its specific TLR3 receptor agonist. The MATWIN program, which is based on a long-standing partnership with some fifteen international laboratories including Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Gilead, GSK, Novartis, Pierre Fabre, Pfizer, Roche and Sanofi, has enabled Tollys to present its state-of-the-art research programs to the world's leading experts in anti-cancer treatments.

www.tollys.fr

contact@tollys.fr